Article Text

other Versions

PDF
Long-term follow-up of relapsing/refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)
  1. Michael Walsh (mwwalsh{at}ucalgary.ca)
  1. Addenbrooke's Hospital, United Kingdom
    1. Afzal Chaudhry (anc35{at}cam.ac.uk)
    1. Addenbrooke's Hospital, United Kingdom
      1. David R.W. Jayne (dj106{at}cam.ac.uk)
      1. Addenbrooke's Hospital, United Kingdom

        Abstract

        Objective: Lymphocytes are a contributor to the pathogenesis of anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AASV). Conventional immunosuppressive therapy is associated with high rates of relapse and toxicity. Humanized monoclonal anti-CD52 antibodies (alemtuzumab, CAMPATH-1H) selectively deplete lymphocytes. We present long-term follow-up results of patients with relapsing/refractory AASV treated with CAMPATH-1H.

        Patients and Methods: Between 1991 and 1999, 71 patients with refractory or relapsing AASV received CAMPATH-1H at Addenbrooke’s Hospital. Other immunosuppressive drugs were discontinued and prednisolone was tapered to 10 mg/day.

        Results: The mean follow-up time was 5 years. 79% had previously received cyclophosphamide (median dose 150 g). At the time of treatment, 42% had renal involvement (median creatinine for the cohort 101 µmol/L excluding 6 patients who were dialysis dependent) and 18% were critically ill from AASV and required the intensive care unit. 60 (85%) obtained a remission after treatment with CAMPATH-1H but 43 relapsed (median 9.2 months). 24 had a remission greater than 1 year of which 10 had a remission of at least 3 years. 31 patients died (median survival time of 106 months). Age over 50 years, dialysis dependency and the development of a severe infection at the time of treatment were associated with an increased risk of death in multivariable analysis. Adverse events were common; 28 patients developed an infection, 3 malignancy and 8 thyroid disease.

        Conclusions: CAMPATH-1H induced remission in most patients with difficult to treat AASV. However, relapse and adverse events were common. Further study of CAMPATH-1H as an induction agent in AASV is warranted.

        • ANCA
        • CAMPATH-1H
        • alemtuzumab
        • vasculitis

        Statistics from Altmetric.com

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.